CD44+/CD24− phenotype predicts a poor prognosis in triple-negative breast cancer

HUI WANG1*, LI WANG2*, YING SONG1, SHUHUAI WANG3, XU HUANG4, QIJIA XUAN1, XINMEI KANG1 and QINGYUAN ZHANG1

1Department of Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081; 2Department of Medical Oncology, The Fourth People's Hospital of Zibo, Zibo, Shandong 255000; Departments of 3Pathology and 4Radiation Oncology, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China

Received October 10, 2015; Accepted March 24, 2017
DOI: 10.3892/ol.2017.6959

Abstract. Cancer stem cells are enriched in triple-negative breast cancer (TNBC) tumor tissues, which present strong capacities of proliferation and tumorigenicity. The present study detected the distribution of cancer stem cell markers cluster of differentiation (CD)44/CD24 and analyzed the clinical outcomes of different CD44/CD24 phenotypes in patients with TNBC. Multivariate Cox regression analyses were performed with regard to the prognostic value of cancer stem cell markers CD44/CD24, aldehyde dehydrogenase 1 and other baseline clinical characteristics, including tumor size, lymph node involved, adjuvant chemotherapy, Ki-67, breast cancer susceptibility gene 1, cellular tumor antigen p53, vimentin and basal-like status. The multivariate analyses showed that three of these factors, CD44/CD24 phenotype, basal-like status and number of lymph nodes involved, had an impact on overall survival. Furthermore, patients with CD44+/CD24− phenotype, basal-like tumors and ≥4 lymph nodes involved had a significantly worse prognosis. The expression of CD44 and CD24 was detected by double-staining immunohistochemistry, which can locate cancer stem cells individually. Overall, the present results indicated that CD44/CD24 status evaluated by double-staining immunohistochemistry constitutes an independent prognostic factor for TNBC.

Introduction

Breast cancer is a highly histological heterogeneous disease comprised of several biologically different phenotypes (1). One of these subtypes, triple-negative breast cancer (TNBC), is defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in the tumor specimen, and comprises 10-20% of all diagnosed breast cancer cases (2,3). Patients diagnosed with TNBC normally have a younger age, higher grade and higher rate of cellular tumor antigen p53 (p53) mutation when compared with those of other breast cancer subtypes (4). Furthermore, due to the lack of hormone receptor and HER2 targets, patients with TNBC do not have access to targeted therapy or adjuvant endocrine treatment. Thus, they have a higher incidence of early local recurrence or distant organ metastases (5). Therefore, novel methods to improve the prognosis of TNBC are urgently required.

According to the cancer stem cell hypothesis (6), cancer stem cells are considered as the source of malignancy, invasion and metastasis. In preclinical study, the cancer stem cell subpopulation is defined by two key characteristics, namely, self-renewal and multi-directional differentiation (7). A previous study by Al-hajj et al demonstrated that as few as 100 epithelial-specific antigen (ESA+)/lineage (Lin−)/cluster of differentiation (CD)44+/CD24− breast cancer cells were able to serially reproduce tumors when transplanted into immunodeficient mice, whereas 200-fold more cells without these surface markers did not possess tumorigenic potential; i.e., these breast cancer stem cells had properties of self-renewal and longevity (8). In addition, the key cell surface markers that can isolate the cancer stem cell subpopulation are CD44+/CD24−, aldehyde dehydrogenase 1 (ALDH1) (9),
Patients and methods

Patients and tissue specimens. A cohort of 1,036 female patients with breast cancer who received breast surgery between Feb 2004 and December 2008 in the Cancer Hospital of Harbin Medical University (Harbin, China) were studied, and 145 eligible patients with TNBC were identified. Patients were aged between 28 and 76 years (median age, 50 years) at enrollment. Immunohistochemistry (ER <1%, PR <1% and HER2 <10%) of breast tumors was not positive by re-staining. Patients were excluded from this cohort if they had undergone radiotherapy, chemotherapy, targeted therapy or adjuvant endocrine treatment prior to surgery. Patients were also excluded if the histological specimens could not be collected or if they had not undergone active follow-up. In addition, the patients who had developed distant organ metastases or T4 tumors prior to surgery were not included in the present study. Consequently, the final study cohort consisted of 145 patients with stage I-IIIa TNBC. For pathological staging, the Tumor-Node-Metastasis staging system in the seventh edition of the American Joint Committee on Cancer was used (15).

Detailed clinical data of patients were collected from hospital registries and medical records. Information about age at diagnosis (<40, 40-49, 50-59 and ≥60 years), menopausal status (premenopausal or postmenopausal), tumor size (<2, 2-5 and ≥5 cm), the number of lymph nodes involved (0, 1-3 and ≥4), pathology (intraductal carcinoma, invasive ductal carcinoma, invasive lobular carcinoma and other types), radiotherapy (yes or no), chemotherapy [no chemotherapy, derivative regimens of cyclophosphamide, adriamycin and fluorouracil (CAF), such as CAF, cyclophosphamide, epirubicin and fluorouracil (CEF), cyclophosphamide, pirarubicin and fluorouracil (CTF), or ifosfamide, epirubicin and fluorouracil (IEF), regimens including taxanes, such as paclitaxel or docetaxel and epirubicin (TE), docetaxel and cyclophosphamide (TC), or docetaxel, adriamycin and cyclophosphamide (TAC), and other regimens], dates of recurrences or metastases and dates of mortality were collected. Disease-free survival (DFS) was defined as the duration from the date of diagnosis to the appearance of a regional recurrence or distant metastasis. Overall survival (OS) was defined as the time from the date of diagnosis to the mortality of the patient. The current study was approved by the Harbin Medical University Medical Ethics Committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients provided written informed consent prior to inclusion in the study.

The suitable formalin-fixed, paraffin-embedded tissues of invasive tumors were consecutively retrieved from the Laboratory of Pathology, and 4-µm sections were cut and used for immunohistochemical staining of Ki-67, p53, androgen receptor (AR), vimentin, breast cancer susceptibility gene 1 (BRCA1), cytokeratin5/6 (CK5/6), epidermal growth factor receptor (EGFR), ALDH1, CD44 and CD24.

Immunohistochemical staining. Expression of Ki-67, p53, AR, vimentin, BRCA1, CK5/6, EGFR and ALDH1 was measured by immunohistochemical staining in formalin-fixed paraffin tissue sections using methods described previously (16,17). Sections were dewaxed in xylene, rehydrated through a graded ethanol series and rinsed in distilled water. Antigen retrieval was achieved by placing the glass slides in citrate (pH 6.0; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) or EDTA buffer (pH 9.0; Sigma-Aldrich; Merck KGaA) for 2 min under high pressure. Sections (4-µm) were stained with the following antibodies obtained from Abcam (Cambridge, UK): anti-Ki-67 (rabbit; polyclonal; catalog no., ab15580; dilution, 1:50), anti-p53 (rabbit; monoclonal; catalog no., ab179477; dilution, 1:400), anti-AR (rabbit; polyclonal; catalog no., ab74272; dilution, 1:50), anti-vimentin (mouse; monoclonal; catalog no., ab9879; dilution, 1:150), anti-BRCA1 (mouse; monoclonal; catalog no., ab16780; dilution, 1:150), anti-CK5/6 (mouse; monoclonal; catalog no., ab17133; dilution, 1:200), anti-EGFR (rabbit; polyclonal; catalog no., ab2430; dilution, 1:25) and anti-ALDH1 (rabbit; monoclonal; catalog no. ab52492; dilution, 1:250). The positive and negative controls were designed in each staining experiment.

Double-staining immunohistochemistry with antibodies for CD44 and CD24 was performed on all cases. The antibodies used were anti-CD44 mouse antibody (monoclonal; catalog no., ab31622; dilution, 1:500; Abcam) and anti-CD44 rabbit antibody (monoclonal; catalog no., ab51037; dilution, 1:100; Abcam). Antigen retrieval was performed under high pressure, and endogenous peroxidase vitality was blocked by incubating the glass slides according to the manufacturer’s protocol. Following primary antibody application, the slides were incubated with MultiVision Polymer Cocktail (anti-rabbit/alkaline phosphatase and anti-mouse/horseradish peroxidase; Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China). CD44 was detected with Nitro-Blue-Tetrazolium working solutions and visualized as a brown stain, whereas CD24 was detected with 3-amin-9-ethylcarbazole and identified as a red stain. Sections were counterstained with hematoxylin, followed by mounting with aqueous ClearMount. A negative control of the primary antibody replaced by Tris phosphate-buffered saline and a positive control of a known CD24+/CD44+ tissue slice were used in each staining experiment.

Evaluation of staining. Staining results were assessed by two pathologists to determine the immunohistochemistry score independently. An average was used for any discrepant staining between cores from the same patient. Cytoplasmic staining for
ALDH1 was graded as 0 if ≤10% of the cells were stained, 1+ when 10-25% of the cells were stained, 2+ when 26-50% of the cells were stained and 3+ when >50% of the cells were stained. Staining sections were visualized using an Axiohot microscope (Carl Zeiss AG, Oberkochen, Germany; magnification, x400). Five fields of view were randomly selected for immunohistochemical scoring. The expression of Ki-67, p53, AR, vimentin, BRCA1, CK5/6 and EGFR were evaluated as previously described (17-21). CD44 was identified as brown mainly in the membranous staining and CD24 was identified as red mainly in the cytoplasmic and membranous staining. The frequencies of CD44+/CD24+ tumor cells were determined as the percentage of cells with brown color staining without much interference from red coloration, whereas CD44-/CD24+ tumor cells were characterized as the cells with intense red staining with absence of brown coloration. CD44+/CD24- cells were cells with brown membranous staining and red cytoplasmic staining. CD44-/CD24- cells exhibited no staining. A tumor was categorized with the CD44+/CD24+ phenotype only when the proportion of CD44+/CD24+ cells was >10%, and the CD44-/CD24+ and CD44-/CD24- phenotypes were categorized in the same way. Tumors were defined as exhibiting the CD44-/CD24- phenotype when none of the three types of positive cells (CD44+/CD24-, CD44+/CD24+ and CD44-/CD24+ cells) reached a proportion of >10%. In addition, if two (12.4%) or three (6.9%) cell types reached a proportion of >10% in one field of view, they were categorized in accordance with the predominant cell type.

Statistical analysis. Associations between CD44/CD24 status and clinical characteristics were assessed using Fisher's exact test and the χ² test for categorical variables. The Kaplan-Meier method was used to calculate DFS and OS curves, and the log-rank test was performed to assess changes in the relative risk of events according to prognostic factors in univariate analysis. In addition, the Cox proportional hazards regression model was used for multivariate analyses to estimate prognostic value [hazard ratios (HRs) and 95% confidence intervals (CIs)] for the two main study outcomes, DFS and OS. All tests were two-sided and P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS version 19.0 (IBM SPSS, Armonk, NY, USA).

Results

Baseline clinical characteristics. A total of 145 patients were enrolled in the present study with a median follow-up time of 76 months, and their baseline clinical characteristics are listed in Table I. The median times for DFS and OS were 67 and 71 months, respectively. A total of 39 patients (26.9%) had suffered recurrence or metastasis and 35 patients (24.1%) had succumbed by the end of follow-up. Overall, lymph node metastasis was recorded in 51.7% of cases, of which 23.4% had 1-3 lymph nodes involved and 28.3% had ≤4 lymph nodes involved. The predominant chemotherapy regimens included derivative regimens of CAF, such as CAF, CEF, CTF or IEF (n=53); and regimens including taxanes, such as TE, TC or TAC (n=43), which accounted for 96 (80.7%) of the 119 patients who underwent adjuvant chemotherapy.

Immunohistochemical expression of the biomarkers. As shown in Table II, 92.4% of cases exhibited a Ki-67 proliferative index >0%, of which 26.9% exhibited an index of 1-10%, 24.8% an index of 11-50% and 40.7% an index of 51-100%. The p53 and BRCA1 mutation carriers accounted for 37.2 and 24.1%, respectively. Immunophenotyping showed that AR was expressed in 11.7% (17/145) of the tumors, and vimentin in 44.1% (64/145). In this group, EGFR and CK5/6 expression was observed in 15.2 and 31.7% of 145 TNBCs, respectively. In addition, 57 tumors (39.3%) were classified as basal-like subtype, and 52 tumors (35.9%) were grade 3+ for ALDH1 staining (Fig. 1).

Immunohistochemical expression of CD44 and CD24. The presence of CD44 and CD24 antigens was analyzed in human breast cancer tissues using double-staining immunohistochemistry. The CD44 and CD24 expression was successfully determined in 145 cases. Fig. 2 shows representative staining patterns of various breast tumors. CD44 was identified as brown mainly in the membranous staining and CD24 was identified as red mainly in the cytoplasmic and membranous staining. In addition, to investigate the association between CD44/CD24 status and patient survival, tumors were classified according to the percentage of cells with different CD44 and CD24 expression, which resulted in four phenotypic groups: CD44+/CD24- (43.4%; 63/145), CD44+/CD24+ (30.3%; 44/145), CD44-/CD24+ (3.4%; 5/145) and CD44-/CD24- (22.8%; 33/145) (Table III). According to the classification, it was inferred that the CD44+/CD24- and CD44+/CD24+ phenotypes accounted for the majority of TNBC cases. In the survival analyses, patients with the CD44-/CD24+ phenotype had a significantly worse prognosis (P<0.005).

Association between CD44/CD24 phenotypes and other clinical characteristics. The distribution of different CD44/CD24 phenotypes (CD44+/CD24-, CD44+/CD24+, CD44-/CD24+ and CD44-/CD24-) was calculated in Table IV. The χ² test identified the following factors to be associated with CD44/CD24 status: Pathology, AR status and vimentin. All four phenotypes appeared to be mainly invasive ductal carcinoma. In addition, the CD44+/CD24+ phenotype contained a comparable amount of invasive lobular carcinoma (P=0.011). The CD44-/CD24- phenotype exhibited increased AR expression (25%) compared with the other three groups (P=0.022). CD44+/CD24- tumors mostly expressed vimentin protein (75.8%; P=0.0001). In addition, CD44+/CD24- cases were more commonly scored as ALDH1 staining grade 3+ tumors when compared with CD44+/CD24+ cases, however, this difference was not statistically significant (50.0 vs. 30.3%, respectively; P=0.378).

DFS analysis. For the prognostic evaluations, adjusted multivariable Cox regression analyses were performed and listed in Table V. In the analysis of CD44/CD24 status, patients with the CD44+/CD24- subtype possessed a slightly increased risk of recurrence or metastasis compared with patients with CD44+/CD24+ phenotype, adjusting for confounders. The estimated HR for CD44+/CD24- subtype in CD44/CD24 status was 2.38 (95% CI, 0.90-6.33; P=0.081). No association was observed between the CD44+/CD24+ phenotype and DFS, nor between CD44+/CD24- status and DFS, with estimated HRs...
being 0.38 (95% CI, 0.03–4.44; P=0.438) and 0.59 (95% CI, 0.18–1.98; P=0.393), respectively.

Notably, lymph node metastasis was associated with DFS in multivariable analysis (P=0.004; Fig. 3A). In the cohort, it was observed that patients with derivative regimens of CAF had a poor prognosis (P=0.024), while regimens including taxanes were associated with a shorter DFS time (P=0.001). Subsequently, additional analyses of data revealed that the majority of patients with ≥4 lymph nodes received regimens including taxanes. In addition, it was observed that patients with vimentin-positive tumors had a poor prognosis (P=0.005).

| Characteristics                     | Patients, n (%) |
|-------------------------------------|-----------------|
| Age at diagnosis, years             |                 |
| <40                                 | 19 (13.1)       |
| 40-49                               | 53 (36.6)       |
| 50-59                               | 48 (33.1)       |
| ≥60                                 | 25 (17.2)       |
| Menopausal status                   |                 |
| Premenopausal                       | 71 (49.0)       |
| Postmenopausal                      | 74 (51.0)       |
| Tumor size, cm                      |                 |
| ≤2                                  | 37 (25.5)       |
| 2.5                                 | 96 (66.2)       |
| >5                                  | 12 (8.3)        |
| Number of lymph nodes involved      |                 |
| 0                                   | 70 (48.3)       |
| 1-3                                 | 34 (23.4)       |
| ≥4                                  | 41 (28.3)       |
| Pathology                           |                 |
| Intraductal carcinoma               | 4 (2.8)         |
| Invasive ductal carcinoma           | 132 (91.0)      |
| Invasive lobular carcinoma          | 4 (2.8)         |
| Other types                         | 5 (3.4)         |
| Radiotherapy                        |                 |
| No                                  | 125 (86.2)      |
| Yes                                 | 20 (13.8)       |
| Chemotherapy                        |                 |
| No chemotherapy                     | 26 (17.9)       |
| Derivative regimens of CAF          | 53 (36.6)       |
| (CAF, CEF, CTF or IEF)              |                 |
| Regimens including taxanes (TE, TC or TAC) | 43 (29.7)       |
| Other regimens                      | 23 (15.9)       |

CAF, cyclophosphamide, adriamycin and fluorouracil; CEF, cyclophosphamide, epirubicin and fluorouracil; CTF, cyclophosphamide, pirarubicin and fluorouracil; IEF, ifosfamide, epirubicin and fluorouracil; TE, paclitaxel or docetaxel and epirubicin; TC, docetaxel and cyclophosphamide; TAC, docetaxel, adriamycin and cyclophosphamide.

OS analysis. The number of lymph nodes involved was strongly associated with OS in multivariable analyses, with an estimated HR for ≥4 lymph nodes of 12.90 (P<0.0001; Fig. 3B).

The roles of CD44/CD24 status and ALDH1 were assessed using multivariable Cox regression analyses in OS (Table V). Notably, for patients with a CD44+/CD24+ phenotype, risk of mortality was statistically significantly increased compared with patients with CD44+/CD24- phenotype (P=0.005; Fig. 4A). The estimated HR for CD44+/CD24+ subtype in CD44/CD24 status was 4.38 (95% CI, 1.57–12.18). Furthermore, no association was observed between CD44+/CD24+ phenotype and OS.
with the estimated HR being 0.89 (95% CI, 0.09-8.99; P=0.920). Although the HR was increased for the CD44+/CD24− phenotype compared with the CD44+/CD24+ subtype, this difference was not statistically significant (HR, 1.24; 95% CI, 0.38-4.01; P=0.722). In this adjusted multivariable analysis, no significant association was observed between ALDH1 and OS in the TNBC cohort. However, the Kaplan-Meier curves of different levels of ALDH1 did separate and the survival of patients with ALDH1 grade 3+ was inferior to those of patients with grade 0, 1+ or 2+ (P=0.571; Fig. 4B). In general, ALDH1 overexpression could be a disadvantage for the survival of patients.

In addition, there was a trend toward an inferior OS for patients with basal-like tumors vs. non-basal-like tumors (P=0.013; Fig. 4C) (Table V). Similarly, no significant difference was observed between OS and clinical characteristics, including tumor size, pathology, radiotherapy, chemotherapy, Ki-67, p53, AR, vimentin or BRCA1.

Discussion

Breast carcinoma is recognized as a heterogeneous disease and presents with distinct histopathological features and clinical behaviors, and a variety of outcomes (22). TNBC is a unique type of breast cancer with a poor prognosis (2). Cancer stem cells are more abundant in TNBC tumor tissues and perform important roles in the recurrence and metastasis of TNBC (6,14). Although several studies have shown that large percentages of CD44+CD24− cells or ALDH1− cells remain in TNBC (18,23-25), the importance of the role of these cancer stem cell subpopulations with regard to the prognosis of patients has not been clearly understood. The present study investigated the association between CD44/CD24 phenotypes and the ALDH1 expression and survival of patients with TNBC following surgical therapy.

Previously, a number of studies (13,26) demonstrated that the expression of TNBC antigens, including C-X-C chemokine receptor type 4 and octamer-binding transcription factor 4, are most prevalent in CD44+/CD24− cells, and may promote the epithelial-mesenchymal transition of the CD44+/CD24− phenotype, facilitating breast cancer recurrence or metastasis. In addition, breast cancer cell lines with a prevalence of CD44+/CD24− cells have a higher potential than others to invade Matrigel in vitro and a high metastatic ability in vivo in the lymph node microenvironment and in distant metastasis (27). Furthermore, in a cohort of 50 patients with TNBC, Idowu et al (24) reported that the tumor tissues with CD44+/CD24− were more likely to have a high Ki-67 proliferation index and be associated with a poor clinical outcome. Other breast cancer specimens in which single staining detected the expression of CD44 and CD24, it was clarified that the tumor tissues with the CD44+/CD24− subtype had a higher median vascular density compared with that in those tissues with the CD44+/CD24+ phenotype; OS analysis of this study showed that patients with the CD44+/CD24+ phenotype may have an unfavorable prognosis (23).

In the present study, the expression of CD24 and CD44 was examined using immunohistochemical double-staining. Results certified that the double-staining pattern did not interfere with the accurate expression of CD44 and CD24, and it could also locate cells with
different expression profiles individually. The percentages of four types of cancer cells (CD44+/CD24-, CD44+/CD24+, CD44+/CD24+ and CD44+/CD24+) in tumors were counted following double-staining immunohistochemistry, and each tumor was defined by the presence of the predominant cell type. No association was observed between DFS and the CD44+/CD24- phenotype, however, OS analysis showed that patients with the CD44+/CD24- phenotype experienced a significantly shorter survival time compared with patients with other phenotypes. The CD44+/CD24- cell population has been associated with a poor prognosis (28), although not in all relevant studies. In a similar study (29), Ezrin and CD44 protein co-expression, which was detected with immunofluorescence double-staining, was shown to be associated with a poor disease-specific survival time in 726 breast cancer patients. In addition, according to the

| Characteristics         | CD44+/CD24- | CD44+/CD24+ | CD44+/CD24+ | CD44+/CD24+ | P-value |
|-------------------------|-------------|-------------|-------------|-------------|---------|
| Pathology               |             |             |             |             | 0.011   |
| Intraductal carcinoma   | 0 (0.0)     | 4 (9.1)     | 0 (0.0)     | 0 (0.0)     |         |
| Invasive ductal carcinoma | 61 (96.8)  | 37 (84.1)   | 4 (80.0)    | 30 (90.9)   |         |
| Invasive lobular carcinoma | 2 (3.2)    | 1 (2.3)     | 1 (20.0)    | 0 (0.0)     |         |
| Other types             | 0 (0.0)     | 2 (4.5)     | 0 (0.0)     | 3 (9.1)     |         |
| Androgen receptor       |             |             |             |             | 0.022   |
| Negative                | 59 (93.7)   | 33 (75.0)   | 5 (100.0)   | 31 (93.9)   |         |
| Positive                | 4 (6.3)     | 11 (25.0)   | 0 (0.0)     | 2 (6.1)     |         |
| Vimentin                |             |             |             |             | 0.000   |
| Negative                | 38 (60.3)   | 32 (72.7)   | 3 (60.0)    | 8 (24.2)    |         |
| Positive                | 25 (39.7)   | 12 (27.3)   | 2 (40.0)    | 25 (75.8)   |         |
| Aldehyde dehydrogenase 1|             |             |             |             | 0.378   |
| Grade 0                 | 23 (36.5)   | 8 (18.2)    | 2 (40.0)    | 12 (36.4)   |         |
| Grade 1+                | 7 (11.1)    | 6 (13.6)    | 1 (20.0)    | 6 (18.2)    |         |
| Grade 2+                | 14 (22.2)   | 8 (18.2)    | 1 (20.0)    | 5 (15.2)    |         |
| Grade 3+                | 19 (30.2)   | 22 (50.0)   | 1 (20.0)    | 10 (30.3)   |         |

CD, cluster of differentiation.
Table V. Multivariate cox-regression analyses of prognosis factors with DFS and OS.

| Prognosis factors | DFS                      | OS                      |
|-------------------|--------------------------|-------------------------|
| Number of lymph nodes involved | HR 95% CI P-value<sup>a</sup> | HR 95% CI P-value<sup>a</sup> |
| 0                 | 1.00                     | 1.00                    |
| 1-3               | 0.96 0.28-3.27 0.949     | 1.75 0.54-5.71 0.353    |
| ≥4                | 5.79 1.73-19.32 0.004    | 12.90 3.57-46.59 0.000  |
| Chemotherapy      |                          |                         |
| No chemotherapy   | 1.00                     | 1.00                    |
| Derivative regimens of CAF (CAF, CEF, CTF or IEF) | 6.00 1.26-28.46 0.024 | 1.36 0.31-5.92 0.681 |
| Regimens including taxanes (TE, TC or TAC) | 11.11 2.61-47.39 0.001 | 1.84 0.54-6.20 0.328 |
| Other regimens    | 2.18 0.46-10.44 0.329    | 0.28 0.05-1.64 0.158    |
| Vimentin          |                          |                         |
| Negative          | 1.00                     | 1.00                    |
| Positive          | 4.15 1.53-11.28 0.005    | 2.88 0.96-8.61 0.059    |
| Basal-like        |                          |                         |
| EGFR and CK5/6 negative | 1.00             | 1.00                    |
| EGFR or CK5/6 positive | 1.96 0.78-4.93 0.151 | 3.17 1.28-7.82 0.013    |
| Aldehyde dehydrogenase 1 |              |                         |
| Grade 0           | 1.00                     | 1.00                    |
| Grade 1+          | 0.61 0.14-2.58 0.605     | 0.57 0.11-2.87 0.492    |
| Grade 2+          | 0.33 0.09-1.23 0.329     | 0.44 0.10-1.94 0.279    |
| Grade 3+          | 1.30 0.42-4.06 1.298     | 1.40 0.44-4.43 0.571    |
| CD44/CD24 status  |                          |                         |
| CD44<sup>+</sup>/CD24<sup>+</sup>   | 2.38 0.90-6.33 0.081     | 4.38 1.57-12.18 0.005   |
| CD44<sup>+</sup>/CD24<sup>+</sup>   | 0.38 0.03-4.44 0.438     | 0.89 0.09-8.99 0.920    |
| CD44<sup>+</sup>/CD24<sup>+</sup>   | 0.59 0.18-1.98 0.393     | 1.24 0.38-4.01 0.722    |

DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; CD, cluster of differentiation; CK5/6, cytokeratin 5/6; CAF, cyclophosphamide, adriamycin and fluorouracil; CEF, cyclophosphamide, epirubicin and fluorouracil; CTF, cyclophosphamide, pirarubicin and fluorouracil; IEF, ifosfamide, epirubicin and fluorouracil; TE, paclitaxel or docetaxel and epirubicin; TC, docetaxel and cyclophosphamide; TAC, docetaxel, adriamycin and cyclophosphamide. *P<0.05 was considered to indicate a statistically significant difference.

Figure 4. Prognostic value of the main clinical and tissue characteristics in triple-negative breast cancer. Kaplan-Meier curves of estimated OS for (A) CD44/CD24 status (B) ALDH1 and (C) basal-like. OS, overall survival; CD, cluster of differentiation; ALDH1, aldehyde dehydrogenase 1.
present data from Kaplan-Meier curves of estimated DFS and OS, the CD44/Cd24 phenotype in TNBC may also be associated with a trend for an increased risk of recurrence or mortality when compared with the CD44/Cd24 phenotype, although this did not reach statistical significance. A previous study from Ahmed et al (30) demonstrated that the CD44/Cd24 phenotype was significantly associated with shorter metastasis-free survival time and decreased 10-year breast cancer survival rate. In the study by Mylona et al (31), the CD44/Cd24 phenotype emerged as a poor prognostic indicator, at least within the group of grade 2 tumors.

Furthermore, ALDH1 is another key cell surface marker isolating the cancer stem cell subpopulation. Charafe-Jauffret et al (32) found that the aggressive and metastatic behaviors of inflammatory breast cancer are mediated by ALDH1+ breast cancer stem cells in mouse xenograft models. In another study involving 577 breast carcinomas, the expression of ALDH1, as defined by immunohistochemistry staining, was significantly associated with a poor clinical outcome (9). In the present study, DFS and OS analyses showed that the survival curve of ALDH1 grade 3+ was inferior to those of grade 0, 1+ or 2+, although the analysis did not reach statistical significance.

In our OS analyses, patients with a basal-like subtype have been more likely to experience shorter OS times. The basal-like breast cancer, which is mostly comprised of TNBCs, is positive for CK5/6 and/or EGFR, and is particularly common in BRCA1 hereditary tumors (17). Moestue et al (33) observed that basal-like xenografts exhibited significantly higher phosphatidylinositol 3-kinase pathway activity than luminal-like xenografts in animal models of breast cancer; i.e., basal-like tumors exhibited worse prognoses compared with luminal-like tumors.

In the present cohort, the involvement of ≥4 lymph nodes has been associated with an increased risk of recurrence and mortality in patients with TNBC. In a cohort of 1,711 patients with the TNBC subtype, Hernandez-Aya et al (16) found that when comparing node-negative and node-positive patients, there was a significant difference in relapse-free survival.

In summary, the present study reported that the CD44/Cd24 phenotype evaluated by double staining immunohistochemistry constitutes an independent prognostic factor for TNBC. Patients with TNBC with the CD44/Cd24 phenotype exhibit a significantly worse prognosis. Additional studies are required to investigate the molecular mechanisms of the aggressive behaviors of cancer stem cells and guide clinical treatment for TNBC.

Acknowledgements

The authors are grateful for the excellent technical assistance of the pathologists in the Cancer Hospital of Harbin Medical University and for the assistance provided for the collection of follow-up data by the staff in the Department of Records. The study was supported by the National Natural Science Foundation of China (grant no. 81270034), the Chunhui Program from Chinese Ministry of Education (grant no. Z2012075) and the Yuweiyan Academician Prominent Youth Foundation from Harbin Medical University (grant no. 2011-2013).

References

1. Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800, 2009.
2. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109: 1721-1728, 2007.
3. Reis-Filho JS and Tutt AN: Triple negative tumours: A critical review. Histopathology 52: 108-118, 2008.
4. Anders C and Carey LA: Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22: 1233-1239, 2008.
5. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L and Uraic G: Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: Results from a population-based study of young women. J Clin Oncol 29: 4373-4380, 2011.
6. Rey A, Morrison SJ, Clarke MF and Weisssman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Vissvader J, Weisssman IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66: 9462-9444, 2006.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
9. Ginestier C, Hui MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jaquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell I: 555-567, 2007.
10. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng Q, et al: Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425: 836-841, 2003.
11. Patrawala L, Calhoun T, Scheident-Koussard R, Zhou J, Claypool K and Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219, 2005.
12. Lin L, Hutzten B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, et al: Evaluation of STAT3 signaling in ALDH1+ and ALDH1-/CD44+/CD24- subpopulations of breast cancer cells. PLoS One 8: e62821, 2013.
13. Honeth G, Bendahl PO, Ringner M, Sallaj L, Gruberger-Saal SK, Lögren K, Grabau D, Fernö M, Borg A and Hegardt C: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R33, 2008.
14. Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Caneselle-Teijeiro JE, Milanese F, Schmitt F and Paredes J: Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J Clin Pathol 64: 937-946, 2011.
15. Sinn HP, Helmchen B and Witekind CH: TNM classification of breast cancer: Changes and comments on the 7th edition. Pathologe 31: 361-366, 2010.
16. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN and Gonzalez-Angulo AM: Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29: 2629-2634, 2011.
17. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
18. Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1 in breast cancer: A story of stem cells and tumor microenvironment. Breast Cancer Res Treat 123: 97-108, 2010.
19. Abdel-Fatah TM, Araoa A, Alsahbi N, Agarwal D, Moseley PM, Perry C, Doherty R, Chan SY, Green AR, Rakha E, et al: Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: A comprehensive analysis in large cohorts. Neoplasia 16: 982-991, 2014.
20. Lee JG and Wu R: Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia 17: 190-200, 2015.
21. Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O’Malley FP and Andrilis IL: Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res Treat 140: 195-205, 2013.
22. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adélaïde J, Koki A, Houvenaeghel G, Hassoun J, et al: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65: 767-779, 2005.
23. Giatromanolaki A, Sivridis E, Fiska A and Koukourakis MI: The CD44+CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients. Med Oncol 28: 745-752, 2011.
24. Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei X, Gao J, Zhao Z and Liu C: Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget 5: 10803-10815, 2014.
25. Pandit TS, Kennette W, Mackenzie L, Zhang G, Al-Katib W, Andrews J, Vantyghem SA, Ormond DG, Allan AL, Rodenhiser DI, et al: Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35: 297-308, 2009.
26. Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E and Vonderhaar BK: Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 11: R82, 2009.
27. Ma L and Jiang T: Clinical implications of Ezrin and CD44 co-expression in breast cancer. Oncol Rep 30: 1899-1905, 2013.
28. Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M and Ellis IO: A CD44+/CD24− phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 133: 979-995, 2012.
29. Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P and Nakopoulou L: The clinicopathologic and prognostic significance of CD44+/CD24−/low and CD44+/CD24− tumor cells in invasive breast carcinomas. Hum Pathol 39: 1096-1102, 2008.
30. Moestue SA, Dam CG, Gorad SS, Kristian A, Bohin A, Melandsmo GM, Engebretsen O, Gribbestad IS and Bjørkøy G: Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res 15: R16, 2013.